RxDoctor Payments Data

Jessica Okrant

Nurse Practitioner · Englewood, CONPI 1356968598

Payments from drug & device makers

$988in general payments, 2019–2025

Across 29 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$247
  • Johnson & Johnson$155
  • Sobi, Inc$124
  • E.r. Squibb & Sons, L.L.C.$116
  • GSK$98
  • Sanofi$91
  • plus $157 from 5 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 80th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$97,703
Medicare patients
201
Services billed
1,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate30$442,678
InqoviDecitabine/Cedazuridine15$74,865
VenclextaVenetoclax18$32,908
EliquisApixaban38$24,946
XareltoRivaroxaban14$18,853
Anagrelide Hcl11$1,297
Hydroxyurea17$562
Ondansetron OdtOndansetron14$311
Mercaptopurine16$241
Ondansetron Hcl13$142
Pantoprazole Sodium16$139
Acyclovir23$136
Lorazepam15$86
Levofloxacin17$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$20$442,67830 claims
Johnson & JohnsonXarelto$155$18,85314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →